Sangamo Therapeutics (SGMO) Net Margin (2016 - 2025)
Historic Net Margin for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to 6012.05%.
- Sangamo Therapeutics' Net Margin fell 60310400.0% to 6012.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 342.22%, marking a year-over-year decrease of 819000.0%. This contributed to the annual value of 169.45% for FY2024, which is 231500.0% down from last year.
- As of Q3 2025, Sangamo Therapeutics' Net Margin stood at 6012.05%, which was down 60310400.0% from 109.18% recorded in Q2 2025.
- Sangamo Therapeutics' Net Margin's 5-year high stood at 18.99% during Q3 2024, with a 5-year trough of 10205.61% in Q1 2024.
- In the last 5 years, Sangamo Therapeutics' Net Margin had a median value of 195.82% in 2022 and averaged 1901.11%.
- Its Net Margin has fluctuated over the past 5 years, first plummeted by -102189900bps in 2024, then skyrocketed by 100391400bps in 2025.
- Sangamo Therapeutics' Net Margin (Quarter) stood at 166.96% in 2021, then dropped by -14bps to 190.76% in 2022, then plummeted by -1448bps to 2952.74% in 2023, then surged by 88bps to 359.94% in 2024, then crashed by -1570bps to 6012.05% in 2025.
- Its Net Margin stands at 6012.05% for Q3 2025, versus 109.18% for Q2 2025 and 475.33% for Q1 2025.